Collegium Pharma (COLL) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Collegium Reports Full-Year 2019 Revenue of $296.7 Million
February 27, 2020 4:02 PM EST 2019 Revenue Growth of 6%, Driven by Xtampza ER revenue growth of 51%
Xtampza® ER Prescriptions Grew 49% in 2019
Collegium Guides to Profitability in 2020
Conference Call Scheduled for Today at 4:30 p.m. ET
STOUGHTON, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Â Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to... More
